Browsing Category

45698 posts

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ — Innovent Biologics,…

CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR

SUZHOU, China, May 7, 2025 /PRNewswire/ — CStone Pharmaceuticals ("CStone", HKEX: 2616), an…

Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression

SHANGHAI, May 7, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest", or…

Bellroy, the popular Australian carry brand, releases much-anticipated luggage styles

The brand renowned for solving carry problems extends their expertise to travel,…

Bellroy, the popular Australian carry brand, releases much-anticipated luggage styles

The brand renowned for solving carry problems extends their expertise to travel,…

Nomad eSIM Drives Global Connectivity and Makes Travel Seamless

SANTA CLARA, Calif., May 7, 2025 /PRNewswire/ — Nomad eSIM, a business line…
Blinq Raises M Series A to Reimagine the Start of Every Professional Relationship

Blinq Raises $25M Series A to Reimagine the Start of Every Professional Relationship

With over 2.5 million users across 500,000 companies in 189 countries, Blinq…
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico

Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico

TAIPEI, May 7, 2025 /PRNewswire/ — Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced…